Nothing exists in the world to make wounds heal faster, on its own with our body’s own healing power, until now. Meet “cassderma rx” – a new, stealth pharmaceutical disruptor that has been granted a patent with multiple allowances on a formulation and methods for stimulating wound healing! In a series of pre-clinical and clinical trials, cassderma scientists used a formulation containing serum-free cell culture nutrient medium supplemented with a non-steroidal anabolic hormone to successfully treat atrophic recalcitrant wounds. There is a global unsolved need for effective wound healing and even today, it is described by the National Council for Biotechnology Information, World Health Organization and National Institutes of Health as a “worldwide pandemic” affecting 6.5 million patients in the U.S. alone costing over $25 billion annually and rapidly growing due to increase in healthcare costs, aging population and sharp rise in obesity and diabetes. In hospitals alone, one thousand people per week expire due to pressure ulcers. In diabetes patients, 84% of amputations are attributed to open wounds. In addition to unsanitary and/or combat conditions, other contributing factors include immune deficiency and malnutrition.
